abstract |
The present application relates to a pharmaceutical composition for oral administration, comprising a monoclonal anti-tumor necrosis factor alpha antibody (TNFα) and at least one or more pharmaceutically acceptable excipients selected from the group comprising: a carboxymethyl-dextran, a chitosan, a cyclodextrin, or a combination of same, as well as the use of said composition in the treatment of inflammatory diseases or autoimmune diseases. |